Seres Therapeutics, Inc. (MCRB)

10.03 +1.21 (+13.68%) As of 10:48AM EST. Market open.

Seres Therapeutics, Inc.

200 Sidney Street
4th Floor
Cambridge, MA 02139
United States
617 945 9626
http://www.serestherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 155

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eric D. Shaff M.B.A.	Pres, CEO & Director	1.09M	N/A	1976
Dr. David S. Ege Ph.D.	Exec. VP & Chief Technology Officer	142.71k	N/A	1974
Mr. Thomas J. DesRosier	Chief Legal Officer, Exec. VP & Sec.	719.55k	N/A	1955
Mr. David A. Arkowitz M.B.A.	Exec. VP, CFO & Head of Bus. Devel.	N/A	N/A	1961
Dr. Matthew R. Henn Ph.D.	Exec. VP & Chief Scientific Officer	N/A	N/A	1975
Mr. Carlo Tanzi	VP of Investor Relations & Corp. Communications	N/A	N/A	N/A
Mr. Jeff York	VP of HR	N/A	N/A	N/A
Ms. Jayne M. Gansler	Exec. VP & Chief People Officer	N/A	N/A	N/A
Dr. John G. Aunins Ph.D.	Sr. Advisor	N/A	N/A	1961
Mr. James R. Weston	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Seres Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.